Silence Therapeutics this week announced that it is closing in on a much-needed financial shot in the arm, inking deals to raise £18.7 million ($28.6 million) through the private placement of 9.5 million shares to certain investors.
After the departure of its CEO last summer — the company’s third top executive to step down in two years — Silence Therapeutics is aiming to rebuild itself as a company with an improved business model that can help it advance drug candidates beyond phase I and realize more value
Silence Therapeutics said this week that it has received clearance from German regulators to start a phase Ib/IIa clinical trial of its lead cancer drug Atu027 in combination with the widely prescribed chemotherapeutic gemcitabine for pancreatic cancer.
Silence Therapeutics last month released its financial results for the first six months of 2012, reporting a sharply increased net loss on charges related to its decision to drop its license to certain RNAi intellectual property.
Silence Therapeutics has appointed Michael Khan as its new chief medical adviser. He will also serve on the company's board of directors.
Khan is an associate professor of medicine at the University of Warwick.
Silence Therapeutics this week announced that it has generated preclinical data showing that its acute lung injury drug Atu111 could boost the survival of mice infected with pneumonia when combined with antibiotics.
Silence Therapeutics this week announced that it has struck a deal under which its delivery technologies will be evaluated by Australian microRNA drug developer Mireven for use with its therapeutic candidates.